AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

HTRA inhibitors

Summary

Novel Ahp-cyclodepsipeptide-based HTRA inhibitors for the treatment of macular degeneration (HTRA1) or cell death in reperfusion-ischemia (HTRA2).

Technology Benefits

First-in-class inhibitors for HTRA
Novel promising drug target for various indications

Technology Application

Ahp-cyclodepsipeptides constitute a novel class of HTRA inhibitors and are thus qualified to be further developed as “first-in-class” drugs for that target.

Detailed Technology Description

Ahp-cyclodepsipeptides represent a suitable scaffold for generating target-tailored inhibitors of serine proteases. They have developed a practical mixed solid- and solution-phase synthesis that allows the customized synthesis of Ahp-cyclodepsipeptides and thus tailored inhibitor synthesis.

Type of Cooperation

Licensing

Application Date

14/05/2018 00:00:00

Application No.

WO2018EP62381 20180514

Classes

- international:
C07K7/06; C07K7/54
- cooperative:
C07K11/00; C12Q1/37; A61K38/00; G01N2500/04

Others

Patent application

ID No.

4907

Country/Region

Germany

For more information, please click Here